Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EU Funding for Clinical Trials of a Placental Malaria Vaccine

Published: Tuesday, March 05, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
PlacMalVac project has received an FP7 EU grant.

PlacMalVac - a project coordinated by University of Copenhagen has received an FP7 EU grant, which will enable the first clinical trial of a VAR2CSA based vaccine to target malaria parasites infecting pregnant women.

The international consortium includes the Centre for Medical Parasitology (CMP) from University of Copenhagen (Denmark), ExpreS2ion Biotechnologies (Denmark), Institut de Recherche pour le Développement (France), European Vaccine Initiative (EVI, Germany), Université d'Abomey-Calavi (Benin), & University of Tübingen (Germany).

The clinical development program was initiated in 2012 with support from the Danish National Advanced Technology Foundation.

Professor Ali Salanti from the University of Copenhagen: “The funding from DNATF allowed us to commence a very ambitious and high risk vaccine development project, and in this project we managed to define and show proof of concept for the malaria vaccine and we are currently addressing manufacturability of the vaccine. The funding from EU FP7 will enable us to continue the development including upstream and downstream process development, GMP production, Phase Ia and Ib human clinical trials, as well as preparations for Phase II clinical trials."

Professor Thor G. Theander from the University of Copenhagen: “This will be the first clinical trial using the parasite antigens that cause severe disease syndromes. The vaccine attempts not to eliminate the infection but to eliminate the disease. At Centre for Medical Parasitology we are all thrilled to have this opportunity and it marks an intermediate highpoint of many years of committed research. If the vaccine is safe it will, however, require many years of continued international support before it can help pregnant women and their unborn children.”

Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies: “We are proud to be part of this significant effort in the fight against malaria. Our partnership with CMP has allowed us to leverage our Drosophila S2 cells-based protein expression platform capabilities to contribute to developing a potential vaccine for the millions of people impacted by placental malaria. Our platform is very well suited for production of complex and challenging antigens and has good scalability, which is one of the reasons why it is the choice of expression platform for this and other malaria projects."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genetic Aberration Paves the Way for New Treatment of Cancer Disease
Research was recently published in Scandinavian Journal of Gastroenterology.
Friday, November 08, 2013
Scientific News
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!